anipamil has been researched along with Arteriosclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frandsen, H; Hansen, BF; Hansen, JF; Mortensen, A | 1 |
| Lyakishev, AA; Orekhov, AN; Tertov, VV | 1 |
| Fleckenstein, A; Fleckenstein-Grün, G; Frey, M; Zorn, J | 1 |
1 review(s) available for anipamil and Arteriosclerosis
| Article | Year |
|---|---|
Antihypertensive, anticalcinotic, and antiarteriosclerotic properties of anipamil, a long-acting new derivative of verapamil.
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcinosis; Calcium Channel Blockers; Humans; Propylamines; Rats | 1989 |
2 other study(ies) available for anipamil and Arteriosclerosis
| Article | Year |
|---|---|
(-)-anipamil retards atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Body Weight; Calcium Channel Blockers; Cholesterol; Disease Models, Animal; Eating; Hyperlipidemia, Familial Combined; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Propylamines; Rabbits; Stereoisomerism | 1995 |
Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists.
Topics: Aorta; Arteriosclerosis; Calcium Channel Blockers; Cell Division; Cells, Cultured; Cholesterol; Endothelium, Vascular; Humans; Lipids; Nifedipine; Propylamines; Verapamil | 1991 |